Processing your request

please wait...

Case Page


Case Status:    DISMISSED    
On or around 12/11/2015 (Other)

Filing Date: November 03, 2015

According to a law firm press release, the complaint alleges on October 23, 2015, Spectrum announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application seeking clearance for Evomela, indicating that the FDA cannot approve the application in its present form. When the truth was revealed, shares dropped causing investors harm.

This case was voluntarily dismissed on December 11, 2015.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States


Ticker Symbol: SPPI
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. Nevada
DOCKET #: 15-CV-02105
JUDGE: Hon. James C. Mahan
DATE FILED: 11/03/2015
CLASS PERIOD END: 10/23/2015
  1. Aldrich Law Firm, Ltd.
  2. The Grant Law Firm, PLLC
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available